http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 17:31:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN